1. South Korea Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
Suheung Co. Ltd.

Suheung Co. Ltd.

KKRX:008490
18,360.00
KRW
-350.00
(-1.87%)
4,280.63EPS
4.84P/E
189.43BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
23,664.19
25,166.5
26,283.02
29,414.9
30,259.3
35,211.04
41,440.54
49,730.21
53,672.45
57,098.08
53,440.08
58,764.41
64,958.23
68,799.53
Basic EPS, GAAP
1,073
1,846
1,974
2,360
1,995
2,303
2,853
4,766
4,829
3,056
550
1,644
3,911
3,516.28
Free Cash Flow per Basic Share
-2,967.19
-846.31
-917.45
1,258.91
-92.49
-1,114.37
-2,300.35
-652.52
2,575.6
-1,013.54
-3,754.47
1,570.26
2,662.68
2,933.74
Dividend per Share
192.64
264.86
257.37
272.19
478.31
485.79
941.29
451.36
656.31
499.93
400.17
254.77
663.15
500.7
Book Value per Share
16,780.92
18,410.09
20,443.68
22,377.75
23,636.72
24,606.97
26,586.05
30,403.49
34,873.69
37,893.33
38,282.75
40,891.63
43,949.59
46,604.27
Tangible Book Value per Share
16,223.79
17,806.92
19,850.78
21,683.95
22,977.71
23,635.82
25,860.63
29,726.91
34,235.79
37,360.22
37,742.63
40,495.12
43,447.39
46,035.08
Basic Weighted Avg Shares
11
12
12
12
12
11
11
11
11
11
11
11
11
11
Sales/Revenue/Turnover
269,989
291,116
304,124
340,361
350,008
393,476
460,728
553,012
596,733
634,966
594,567
653,264
722,309
765,899
Operating Margin (%)
9.32
10.01
11.13
11.79
10.65
9.99
10.29
13.44
11.66
9.76
7.23
5.18
7.02
8.14
Depreciation Expense
18,515
18,845
20,734
23,630
24,997
26,654
29,830
34,357
38,187
35,548
36,434
39,855
40,595
41,820
Net Income, GAAP
12,242
21,354
22,841
27,308
23,076
25,736
31,719
52,999
53,689
33,985
6,119
18,276
43,489
39,144
Effective Tax Rate (%)
15.72
10.28
8.59
8.96
14.73
16.24
16.75
17.87
20.78
21.85
36.67
30.98
12.32
22.16
Profit Margin (%)
4.53
7.34
7.51
8.02
6.59
6.54
6.88
9.58
9
5.35
1.03
2.8
6.02
5.11
Working Capital
48,493
45,439
73,697
54,056
-5,129
20,097
68,262
46,760
82,229
118,628
-10,263
65,429
97,453
118,576
LT Debt
118,753
111,745
147,187
119,746
72,096
118,577
176,902
117,107
137,540
172,933
74,237
125,069
144,864
136,586
Total Equity
218,229
237,288
263,042
288,439
300,841
308,172
328,995
376,982
429,868
469,724
477,069
507,774
541,017
576,835
Return on Invested Capital (%)
4.9
5.86
6.34
6.9
5.84
5.82
6.39
8.84
7.33
5.85
2.99
2.46
4.57
4.92
Return on Capital (%)
4.16
6.09
5.33
5.52
4.69
5.1
5.52
7.82
7.24
4.39
1.74
3.1
5.72
4.42
Return on Common Equity (%)
6.59
10.49
10.16
11.02
8.73
9.47
11.14
16.73
14.79
8.4
1.44
4.15
9.22
7.92

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
290,216
318,440
301,140
LT Borrowings
143,764
128,087
135,665
LT Finance Leases
1,101
1,025
921
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
240,729
205,461
189,425

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
464,696
480,370
496,025
Cash, Cash Equivalents & STI
58,678
67,427
71,690
Accounts Receivable, Net
114,177
137,550
147,757
Inventories
269,885
252,819
253,863
Total Current Liabilities
367,243
393,077
377,449
Payables & Accruals
- -
- -
- -
ST Debt
290,216
318,440
301,140
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.56%
7.57%
6.55%
Free Cash Flow
31.77%
-87.11%
69.61%
Net Income, GAAP
32.51%
43.85%
137.96%
Sales/Revenue/Turnover
9.27%
5.68%
10.57%
Total Cash Common Dividend
24.59%
25.12%
160.36%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
165,340
172,765
166,593
148,566
653,264
2025
180,841
190,021
185,046
166,400
722,309
2026
201,552
212,900
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
460
170
957
55.64
1,644
2025
533
2,153
807.82
416.52
3,911
2026
1,060.78
1,231
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
154.62
99.74
- -
- -
254.77
2025
462.61
200.5
-0.01
- -
663.15
2026
0.53
499.92
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Joo-Hwan Yang
Full Time Employees
1,295
Sector
Process industries
Industry
Chemicals: major diversified
Address
61, Osongsaengmyeong-ro Cheongju-si NC South Korea 130-845
IPO Date
Mar 27, 1990
Website
suheung.com
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
AARTI Industries Ltd (NSE:AARTIIND)
Aether Industries Ltd. (NSE:AETHER)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
Suheung Co., Ltd. (008490.KS) manufactures and sells hard and soft capsules for the pharmaceutical, nutraceutical, and health supplement industries. The company produces empty two-piece hard capsules under the Embocaps brand; soft gelatin capsules; solid dosage forms including tablets, powders, and granules; semi-solid forms such as fluidity and concentrated liquids; and jelly products like gummies, sticky, and water jellies. It also offers medical supplies encompassing prescription medicines, over-the-counter drugs such as antipyretic-analgesics, cold medicines, digestive medicines, liver-treatment medicines, and nutritional supplements; quasi-drugs including low-content vitamin-cosmetic products, multi-vitamins, toothpaste, effervescent tablets, and chewable tablets; and raw materials like gelatins and collagens used in capsules, adhesives, cosmetics, and food. Founded in 1973 and headquartered in Cheongju-si, South Korea, at 61 Osongsaengmyeong-ro, Suheung operates through two main segments—capsules and gelatin—with approximately 742 employees and vertically integrated production facilities including the Osong plant. The company serves domestic Korean markets and exports to global pharmaceutical clients, positioning itself as a key supplier of high-quality empty capsules and contract manufacturing services with regulatory support and packaging solutions. Its operations emphasize cutting-edge technology, productivity, and compliance for sectors like drug manufacturers-specialty and generic, specialty chemicals, and healthcare. In recent developments, Suheung launched EMBOCAPS AP60 in May 2024, a delayed-release hard capsule offering over 60 minutes of acid protection using a patented hypromellose and pectin blend without shellacs, phthalates, or coatings, aimed at safeguarding sensitive ingredients like probiotics; this innovation supports expanded production via a new Alpha plant. The company continues strategic efforts outlined in its 2023 Sustainability Report to establish a global comprehensive materials business foundation in 2024 through targeted growth strategies. Suheung maintains its focus on R&D, quality innovation, and market leadership without reported major acquisitions, partnerships, or reorganizations in the last 1-2 years.